Characterization of protoberberine analogs employed as novel human P2X{sub 7} receptor antagonists

Lee, Ga Eun; Lee, Won-Gil; Lee, Song-Yi; Lee, Cho-Rong; Park, Chul-Seung; Chang, Sunghoe; Park, Sung-Gyoo; Song, Mi-Ryoung; Kim, Yong-Chul

doi:10.1016/j.taap.2011.02.009

Title: Characterization of protoberberine analogs employed as novel human P2X{sub 7} receptor antagonists

Full Record
Other Related Research

Abstract

The P2X{sub 7} receptor (P2X{sub 7}R), a member of the ATP-gated ion channel family, is regarded as a promising target for therapy of immune-related diseases including rheumatoid arthritis and chronic pain. A group of novel protoberberine analogs (compounds 3-5), discovered by screening of chemical libraries, was here investigated with respect to their function as P2X{sub 7}R antagonists. Compounds 3-5 non-competitively inhibited BzATP-induced ethidium ion influx into hP2X{sub 7}-expressing HEK293 cells, with IC{sub 50} values of 100-300 nM. This antagonistic action on the channel further confirmed that both BzATP-induced inward currents and Ca{sup 2+} influx were strongly inhibited by compounds 3-5 in patch-clamp and Ca{sup 2+} influx assays. The antagonists also effectively suppressed downstream signaling of P2X{sub 7} receptors including IL-1{beta} release and phosphorylation of ERK1/2 and p38 proteins in hP2X{sub 7}-expressing HEK293 cells or in differentiated human monocytes (THP-1 cells). Moreover, IL-2 secretion from CD3/CD28-stimulated Jurkat T cell was also dramatically inhibited by the antagonist. These results imply that novel protoberberine analogs may modulate P2X{sub 7} receptor-mediated immune responses by allosteric inhibition of the receptor. - Graphical abstract: Display Omitted

Authors:

Lee, Ga Eun; Lee, Won-Gil; Lee, Song-Yi; Lee, Cho-Rong; Park, Chul-Seung ^[1]; Chang, Sunghoe ^[2]; Park, Sung-Gyoo; Song, Mi-Ryoung ^[1]; Kim, Yong-Chul ^[1]

School of Life Sciences, Gwangju Institute of Science and Technology (GIST), Gwangju 500-712 (Korea, Republic of)
Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul 110-799 (Korea, Republic of)

Publication Date:: Fri Apr 15 00:00:00 EDT 2011

OSTI Identifier:: 21535273

Resource Type:: Journal Article

Journal Name:: Toxicology and Applied Pharmacology

Additional Journal Information:: Journal Volume: 252; Journal Issue: 2; Other Information: DOI: 10.1016/j.taap.2011.02.009; PII: S0041-008X(11)00055-X; Copyright (c) 2011 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Journal ID: ISSN 0041-008X

Country of Publication:: United States

Language:: English

Subject:: 60 APPLIED LIFE SCIENCES; ADENOSINE; ATP; CALCIUM IONS; ENZYME IMMUNOASSAY; HUMAN POPULATIONS; INHIBITION; MONOCYTES; PHOSPHORYLATION; RECEPTORS; RHEUMATIC DISEASES; THERAPY; BIOASSAY; BIOLOGICAL MATERIALS; BLOOD; BLOOD CELLS; BODY FLUIDS; CHARGED PARTICLES; CHEMICAL REACTIONS; DISEASES; IMMUNOASSAY; IONS; LEUKOCYTES; MATERIALS; MEDICINE; MEMBRANE PROTEINS; NUCLEOSIDES; NUCLEOTIDES; ORGANIC COMPOUNDS; POPULATIONS; PROTEINS; RIBOSIDES

Citation Formats


                    Lee, Ga Eun, Lee, Won-Gil, Lee, Song-Yi, Lee, Cho-Rong, Park, Chul-Seung, Chang, Sunghoe, Park, Sung-Gyoo, Song, Mi-Ryoung, and Kim, Yong-Chul. Characterization of protoberberine analogs employed as novel human P2X{sub 7} receptor antagonists.  United States: N. p., 2011. 
        Web.  doi:10.1016/j.taap.2011.02.009.

Copy to clipboard


                    Lee, Ga Eun, Lee, Won-Gil, Lee, Song-Yi, Lee, Cho-Rong, Park, Chul-Seung, Chang, Sunghoe, Park, Sung-Gyoo, Song, Mi-Ryoung, & Kim, Yong-Chul. Characterization of protoberberine analogs employed as novel human P2X{sub 7} receptor antagonists.  United States.  https://doi.org/10.1016/j.taap.2011.02.009

Copy to clipboard


                    Lee, Ga Eun, Lee, Won-Gil, Lee, Song-Yi, Lee, Cho-Rong, Park, Chul-Seung, Chang, Sunghoe, Park, Sung-Gyoo, Song, Mi-Ryoung, and Kim, Yong-Chul. 2011.  
        "Characterization of protoberberine analogs employed as novel human P2X{sub 7} receptor antagonists".  United States.  https://doi.org/10.1016/j.taap.2011.02.009.

Copy to clipboard


                    
@article{osti_21535273,

  title        = {Characterization of protoberberine analogs employed as novel human P2X{sub 7} receptor antagonists},

  author       = {Lee, Ga Eun and Lee, Won-Gil and Lee, Song-Yi and Lee, Cho-Rong and Park, Chul-Seung and Chang, Sunghoe and Park, Sung-Gyoo and Song, Mi-Ryoung and Kim, Yong-Chul},

  abstractNote = {The P2X{sub 7} receptor (P2X{sub 7}R), a member of the ATP-gated ion channel family, is regarded as a promising target for therapy of immune-related diseases including rheumatoid arthritis and chronic pain. A group of novel protoberberine analogs (compounds 3-5), discovered by screening of chemical libraries, was here investigated with respect to their function as P2X{sub 7}R antagonists. Compounds 3-5 non-competitively inhibited BzATP-induced ethidium ion influx into hP2X{sub 7}-expressing HEK293 cells, with IC{sub 50} values of 100-300 nM. This antagonistic action on the channel further confirmed that both BzATP-induced inward currents and Ca{sup 2+} influx were strongly inhibited by compounds 3-5 in patch-clamp and Ca{sup 2+} influx assays. The antagonists also effectively suppressed downstream signaling of P2X{sub 7} receptors including IL-1{beta} release and phosphorylation of ERK1/2 and p38 proteins in hP2X{sub 7}-expressing HEK293 cells or in differentiated human monocytes (THP-1 cells). Moreover, IL-2 secretion from CD3/CD28-stimulated Jurkat T cell was also dramatically inhibited by the antagonist. These results imply that novel protoberberine analogs may modulate P2X{sub 7} receptor-mediated immune responses by allosteric inhibition of the receptor. - Graphical abstract: Display Omitted},

  doi          = {10.1016/j.taap.2011.02.009},

  url          = {https://www.osti.gov/biblio/21535273},
  journal      = {Toxicology and Applied Pharmacology},

  issn         = {0041-008X},

  number       = 2,

  volume       = 252,

  place        = {United States},

  year         = {Fri Apr 15 00:00:00 EDT 2011},

  month        = {Fri Apr 15 00:00:00 EDT 2011}

}

Copy to clipboard

Journal Article:

https://doi.org/10.1016/j.taap.2011.02.009

Other availability

Find in Google Scholar

Search WorldCat to find libraries that may hold this journal

Save / Share:

Export Metadata

Save to My Library

Similar records in OSTI.GOV collections:

Nickel differentially regulates NFAT and NF-{kappa}B activation in T cell signaling

Journal Article Saito, Rumiko; Hirakawa, Satoshi; Ohara, Hiroshi; ... - Toxicology and Applied Pharmacology

Nickel is a potent hapten that induces contact hypersensitivity in human skin. While nickel induces the maturation of dendritic cells via NF-{kappa}B and p38 MAPK activation, it also exerts immunosuppressive effects on T cells through an unknown mechanism. To elucidate the molecular mechanisms of its effects on T cells, we examined the effects of NiCl{sub 2} on mRNA expression in human CD3+ T cells stimulated with CD3 and CD28 antibodies. Using a DNA microarray and Gene Ontology, we identified 70 up-regulated (including IL-1{beta}, IL-6 and IL-8) and 61 down-regulated (including IL-2, IL-4, IL-10 and IFN-{gamma}) immune responsive genes in NiCl{submore »« less
https://doi.org/10.1016/j.taap.2011.04.017
Murine T cell activation is regulated by surfen (bis-2-methyl-4-amino-quinolyl-6-carbamide)

Journal Article Warford, Jordan - Biochemical and Biophysical Research Communications

Highlights: •Surfen is the first inhibitor of glycosaminoglycan function to be studied in murine T cells. •Surfen reduces T cell proliferation stimulated in vitro and in vivo. •Surfen reduces CD25 expression in T cells activated in vivo but not in vitro. •Surfen increases T cell proliferation when T cell receptor activation is bypassed. •Surfen’s effects are blocked by co-administration of heparin sulfate. -- Abstract: Surfen (bis-2-methyl-4-amino-quinolyl-6-carbamide) binds to glycosaminoglycans (GAGs) and has been shown to influence their function, and the function of proteoglycans (complexes of GAGs linked to a core protein). T cells synthesize, secrete and express GAGs and proteoglycansmore »« less
https://doi.org/10.1016/J.BBRC.2013.11.119
Molecular mechanisms for Kv1.3 potassium channel current inhibition by CD3/CD28 stimulation in Jurkat T cells

Journal Article Matsushita, Yuichiro; Ohya, Susumu; Itoda, Haruna; ... - Biochemical and Biophysical Research Communications

In T lymphocyte, activation of Kv1.3 channel, the major voltage-dependent K{sup +} channel, is an essential step for cell proliferation in immune responses. Here, effects of anti-CD3 and anti-CD28 antibodies on Kv1.3 current were examined in three types of human T lymphocyte derived cell lines, Jurkat E6-1, p56lck-kinase deficient mutant JCaM.1, and CD45-phosphatase deficient mutant J45.01. Kv1.3 current was partly reduced by CD3 stimulation and more strongly by addition of anti-CD28 antibody in E6-1. In JCaM.1, Kv1.3 current responses to anti-CD28/CD3 antibodies were similar to those in E6-1. In J45.01, CD3 stimulation partly inhibited Kv1.3 current, but the additive reductionmore »« less
https://doi.org/10.1016/j.bbrc.2008.06.118
Inorganic arsenic represses interleukin-17A expression in human activated Th17 lymphocytes

Journal Article Morzadec, Claudie; Macoch, Mélinda; Robineau, Marc; ... - Toxicology and Applied Pharmacology

Trivalent inorganic arsenic [As(III)] is an efficient anticancer agent used to treat patients suffering from acute promyelocytic leukemia. Recently, experimental studies have clearly demonstrated that this metalloid can also cure lymphoproliferative and/or pro-inflammatory syndromes in different murine models of chronic immune-mediated diseases. T helper (Th) 1 and Th17 lymphocytes play a central role in development of these diseases, in mice and humans, especially by secreting the potent pro-inflammatory cytokine interferon-γ and IL-17A, respectively. As(III) impairs basic functions of human T cells but its ability to modulate secretion of pro-inflammatory cytokines by differentiated Th lymphocytes is unknown. In the present study,more »« less
https://doi.org/10.1016/J.TAAP.2012.05.004
Erlotinib inhibits T-cell-mediated immune response via down-regulation of the c-Raf/ERK cascade and Akt signaling pathway

Journal Article Qiong, Luo; Yanhong, Gu; Wei, Zheng; ... - Toxicology and Applied Pharmacology

Erlotinib is a potent inhibitor of epidermal growth factor receptor tyrosine kinase and has been demonstrated to treat advanced or metastatic non-small cell lung cancer to prolong survival after failure of first-line or second-line chemotherapy. However, little is known about its effects on immune system. In the present study, we aimed to investigate the immunosuppressive activity of erlotinib on T lymphocytes both in vitro and in vivo, and further explore its potential molecular mechanism. Erlotinib exerted a significant inhibition on the T cell proliferation and activation induced by concanavalin A, anti-CD3 plus anti-CD28, staphylococcal enterotoxin B or phorbol myristate acetatemore »« less

Similar Records